

Dr. Humberto Fernandez-Miro MD

Regenerative Medicine Specialist with a strong background in medical research and over 25 years of practicing medicine in his hometown of Miami, Florida.

PROFESSIONAL HISTORY

Principal Investigator Poner Global Health Clinical Trials 330 sw 27th Ave, suite 605-606 Miami, FL 33135	July 2016 - Present
Clinical and Sub P.I. Genoma Research Group Inc. 2720 sw 97th Ave, suite 102 Miami, FL 33165	March 2012 - Present
Clinical Investigator Doral Research Center 10454 NW 31 Terrace Doral, FL 33172	July 2011 - Aug. 2013
Family Practitioner 401 Miracle Mile, suite 302 Coral Gables, FL 33134	March 2004 - Present
Family Practitioner 777 East 25th Street, suite 516 Hialeah, FL 33013	Dec. 1998 - Feb. 2004
Family Practitioner 1435 West 49th Place, suite 301	Aug. 1993 - Nov. 1998

Hialeah, FL 33112

Family Practitioner

Jan. 1996 - Sep. 1999

301 nw 42nd Ave, suite 303

Miami, FL 33126

House Physician

Sep. 1992 - Dec 1994

Baptist Hospital

Miami, FL

Surgical Assistant

Aug. 1992 - Dec. 1993

Miami Heart Institute

Miami Beach, FL

EDUCATION / MEDICAL RESEARCH BACKROUD

University of Miami, Florida

Dec. 1992

Medicine Course Review

510 Hours Category I

Counting Medical Education

FLEX Exam

March 1993

Miami, Florida

Basic Science

Clinical Science

Internal Medicine PGY 1

Jan. 1993 -

Dec. 1993

Sub-internship in Internal Medicine

Sep. 1992 - Dec. 1992

MEDICAL BACKGROUND

- Residency program specializing in Anesthesiology and Reanimation for several years.
- Worked in Intensive Care with management of critical patients Post-operative.

- Performed full patient family histories and physical examinations with Pre and Post-operative care and management.

MEDICAL RESEARCH EXPERIENCE

- Effects of Metforming HCL in Combination with Colesevelam HCL, Compared to Metformin HCL alone, as Initial Therapy in Drug naïve subjects with Type 2 Diabetes Mellitus, and the Effects of colesevelam HCL on the Lipoid Profile in subjects with Pre diabetes.
- Multicenter Placebo Controlled Double-Blind Phase III Study to Determine the Efficacy and Safety of an Investigative Anti-epileptic in the Treatment of Generalized Tonic-Clinic Seizures in Refractory Patients.
- A Phase III Protocol to evaluate Pharmacokinetic comparison of Three NPH Insulin Preparations.
- Comparative Randomized Bioavailability Study of a combination Antihistamine and Decongestant Caplet given as a Single-Dose.
- Randomized, Multicenter, double-blind, parallel, Placebo-controlled study of the effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects with Type 2 Diabetes Mellitus (Johnson & Johnson Pharmaceutical research & development).
- A multicentre, international, randomized, parallel group, double blind study to evaluate cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high cardiovascular risk. (Boehringer Ingelheim).
- Chronic Idiopathic Constipation. Phase III, synergy Pharmaceuticals, 2014-2015
- Crohn's Disease, Salix Pharmaceutical, Inc 2014-Present
- Clostridium Deficiency vaccine Prevention, Sanafi-Pasteur Pharmaceuticals, 2014-Present